Conv. Plasma
Nigella Sativa
Peg.. Lambda

All colchicine studies
Meta analysis
Home COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -36% Improvement Relative Risk Progression -7% primary Ventilation -30% ICU admission 76% Hospitalization time 4% Colchicine  COLVID-19  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 152 patients in Italy (April 2020 - May 2021) Lower ICU admission with colchicine (not stat. sig., p=0.21) Perricone et al., European J. Internal.., Oct 2022 Favors colchicine Favors control

Treatment with COLchicine in hospitalized patients affected by COVID-19: the COLVID-19 trial

Perricone et al., European Journal of Internal Medicine, doi:10.1016/j.ejim.2022.10.016, COLVID-19, NCT04375202
Oct 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 152 hospitalized patients in Italy, showing no significant difference in outcomes with colchicine treatment. Table 2 shows 13% of patients treated with antivirals in the colchicine arm, however 16.9% were treated with one specific antiviral (HCQ).
risk of death, 36.4% higher, RR 1.36, p = 0.77, treatment 7 of 77 (9.1%), control 5 of 75 (6.7%).
risk of progression, 7.1% higher, RR 1.07, p = 1.00, treatment 11 of 77 (14.3%), control 10 of 75 (13.3%), mechanical ventilation, ICU, or death, primary outcome.
risk of mechanical ventilation, 29.9% higher, RR 1.30, p = 1.00, treatment 4 of 77 (5.2%), control 3 of 75 (4.0%).
risk of ICU admission, 75.6% lower, RR 0.24, p = 0.21, treatment 1 of 77 (1.3%), control 4 of 75 (5.3%), NNT 25.
hospitalization time, 4.1% lower, relative time 0.96, p = 0.69, treatment mean 14.1 (±10.4) n=77, control mean 14.7 (±8.1) n=75.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Perricone et al., 31 Oct 2022, Randomized Controlled Trial, Italy, peer-reviewed, mean age 69.1, 40 authors, study period 18 April, 2020 - 12 May, 2021, dosage 1.5mg daily, 2mg daily for >100kg, trial NCT04375202 (history) (COLVID-19).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial
Carlo Perricone, Mirko Scarsi, Antonio Brucato, Paola Pisano, Erika Pigatto, Cecilia Becattini, Antonella Cingolani, Francesco Tiso, Roberto Prota, Lina Rachele Tomasoni, Maurizio Cutolo, Marika Tardella, Davide Rozza, Carlo Zerbino, Massimo Andreoni, Venerino Poletti, Elena Bartoloni, Roberto Gerli, Giacomo Cafaro, Monia Mendeni, Enrico Colombo, Marta Del Medico, Paola Cabras, Mauro Giovanni Schiesaro, Laura Franco, Massimo Fantoni, Lara Friso, Valter Gallo, Franco Franceschini, Sabrina Paolino, Fausto Salaffi, Carlo Scirè, Anna Zanetti, Claudia Diana, Angelina Passaro, Rosario Foti, Francesco Saverio Serino, Maurizio Cassol, Giampaolo Bucaneve, Rosalba Elisabetta Rocchi
European Journal of Internal Medicine, doi:10.1016/j.ejim.2022.10.016
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Ethics Statement The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the National Ethics Committee at the Lazzaro Spallanzani Institute. Author Contributions The trial was promoted by the Italian Society of Rheumatology (SIR), the Italian Society of Infectious and Tropical Diseases (SIMIT) and the Italian Thoracic Society (ITS-AIPO). All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final Disclosure The authors declare no conflicts of interest in this work.
Alunno, Najm, Mariette, Marco, Emmel et al., Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219725
Biswas, Sarma, Effect of microtubule disruption on neuronal spread and replication of demyelinating and nondemyelinating strains of mouse hepatitis virus in vitro, J Virol
Bonaventura, Vecchié, Dagna, Tangianu, Abbate et al., Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation, Inflamm Res
Booth, Reed, Ponzo, Yassaee, Aral et al., Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis, PLoS One
Carvelli, Demaria, Vély, Batista, Benmansour et al., None
Cordier, Dault, Guervilly, Simeone, Gainnier et al., Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis, Nature
Cummings, Baldwin, Abrams, Jacobson, Meyer et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet
Da, Roura-Piloto, Moral-Escudero, Bernal, Albendín-Iglesias et al., Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID), Int J Gen Med
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open
Diaz, Orlandini, Castellana, Caccavo, Corral et al., Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial, JAMA Netw Open
Dorward, Yu, Hayward, Saville, Gbinigie et al., Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial, Br J Gen Pract
Ferritin, None
Gaitán-Duarte, Álvarez-Moreno, Rincón-Rodríguez, Yomayusa-González, Cortés et al., Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial, EClinicalMedicine
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Gendelman, Amital, Bragazzi, Watad, Chodick, Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis, Autoimmun Rev
Gorial, Maulood, Abdulamir, Alnuaimi, Abdulrrazaq et al., Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection, Ann Med Surg (Lond)
Guan, Ni, Hu, Liang, Ou et al., None
Kim, Garg, 'halloran, Whitaker, Pham et al., Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease
Kow, Lee, Ramachandram, Hasan, Ming et al., The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials, Immun Inflamm Dis
Lan, Hsu, Lai, Chang, Lu et al., Effect of colchicine on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials, Ann Med
Linn, Linn, Gurel, Hudon, Fortin et al., Abbreviated guidelines for scoring the Cumulative Illness Rating Scale (CIRS) in family practice, J Am Geriatr Soc
Lopes, Bonjorno, Giannini, Amaral, Menezes et al., Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebocontrolled clinical trial, RMD Open
Lu, Yang, Liu, Ding, Ou et al., Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine, Biotech
Mareev, Orlova, Plisyk, Pavlikova, Akopyan et al., Proactive antiinflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study, Kardiologiia
Melillo, Napolano, Loffi, Regazzoni, Boccellino et al., Myocardial injury in patients with SARS-CoV-2 pneumonia: Pivotal role of inflammation in COVID-19, Eur J Clin Invest
Merad, Martin, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat Rev Immunol
Mikolajewska, Fischer, Piechotta, Mueller, Metzendorf et al., Colchicine for the treatment of COVID-19, Cochrane Database Syst Rev
Ozen, Demirkaya, Erer, Livneh, Ben-Chetrit et al., EULAR recommendations for the management of familial Mediterranean fever, Ann Rheum Dis, doi:10.1136/annrheumdis-2015-208690
Perricone, Bartoloni, Gerli, Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19, Reumatologia, doi:10.5114/reum.2020.100088
Perricone, Triggianese, Bartoloni, Cafaro, Bonifacio et al., The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19, J Autoimmun
Recovery Collaborative Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Richette, Doherty, Pascual, Barskova, Becce et al., updated EULAR evidence-based recommendations for the management of gout, Ann Rheum Dis, doi:10.1136/annrheumdis-2016-209707
Richter, Boldescu, Graf, Streicher, Dimoglo et al., Synthesis, Biological Evaluation, and Molecular Docking of Combretastatin and Colchicine Derivatives and their hCE1-Activated Prodrugs as Antiviral Agents, ChemMedChem
Romeo, Barbagelata, Chiabrando, Damonte, Moras et al., The Effect of Colchicine on Mortality, Mechanical Ventilation, and Length of Stay in Patients With COVID-19 Infection: An Updated Systematic Review and Meta-analysis of Randomized Clinical Trials, Am J Ther
Salehzadeh, Pourfarzi, Ataei, The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study, Mediterr J Rheumatol
Salo, Lehtonen, Auranen, Baum, Leino, Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations, Vaccine
Scarsi, Piantoni, Colombo, Airó, Richini et al., Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217712
Sefik, Qu, Junqueira, Kaffe, Mirza et al., Inflammasome activation in infected macrophages drives COVID-19 pathology, Nature
Shionoya, Taniguchi, Kasai, Sakuma, Imai et al., Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study, PLoS One
Slobodnick, Shah, Krasnokutsky, Pillinger, Update on colchicine, Rheumatology
Tardif, Bouabdallaoui, Allier, Gaudet, Shah et al., Colchicine for communitytreated patients with COVID-19 (COLCORONA): a phase 3, randomised, doubleblinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Vrachatis, Papathanasiou, Giotaki, Iliodromitis, Papaioannou et al., Repurposing colchicine's journey in view of drug-to-drug interactions. A review, Toxicol Rep
Wang, Liang, Peng, Wei, Liu et al., China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop